Neothetics is on the road now to fund the continued development of their injection-based approach to fat loss. It’s a smallish deal of $4.3M shares, with a $13-15 price range.

In the news today due to a merger with Actavis that values Allergan at $66 billion, Allergan is a Zacks Rank #2 (Buy).

We've paid some attention and even owned ZLTQ at one time as a way to play into the desires of people to improve their appearance. It's a proven market. Zeltiq reports earnings tonight and so far the company has executed well.

ATHN reported October 16

Rapid growth in the medical device industry and changes in the regulatory environment have propelled valuations in the medtech sector to the high end of the range.